Amarin's drug Vascepa, a treatment for high triglyceride levels, was approved by the Food and Drug Administration this summer. While the company was able to successfully jump over this regulatory hurdle, it is currently trying to obtain New Chemical Entity, or NCE, status for its flagship drug. An NCE designation would give Vascepa five years of market exclusivity, while failure to obtain this status would result in only three years of protection. health care bureau chief Brenton Flynn and analyst Max Macaluso discuss the potential impact of this decision on Amarin going forward.

Amarin has performed exceptionally well year to date -- but for every successful biotech stock, there are a plethora of failures. It's essential as an investor to diversify your portfolio with both speculative plays and more stable, long-term stocks. In our free report "3 Stocks That Will Help You Retire Rich," we reveal both stocks and strategies that can help you build wealth over the long term. Click here to get your copy today.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.